Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
₩ 3235
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very weak growth
Data is available to registered users only
Data is available to registered users only
About
iNtRON Biotechnology, Inc. develops biopharmaceuticals for the prevention and treatment of human diseases worldwide. It develops bacteriophage and endoricin drugs. The company was founded in 1999 and is headquartered in Seongnam-si, South Korea.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. Specifically, the stock is overvalued on EV/EBITDA.
Data is available to registered users only
Buy
Sell